+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • MORE
Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. It is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc Key Recent Developments

Apr 10,2019: Astellas and Concerto HealthAI to Launch Real-World Evidence Initiative on Acute Myeloid Leukemia Focused on Improving Patient Treatment and Outcomes
Apr 03,2019: Astellas announces key senior leadership promotions and new hire in Medical and Development organization
Mar 05,2019: ReForm Biologics announces collaboration agreement with Astellas Pharma
Jan 17,2019: Actinium successfully completes first module of collaborative research program with Astellas; second module initiated
Jan 10,2019: Astellas announces key Senior Leadership promotions and new hire in Medical and Development Organization

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • MORE
Section 1 - About the Company
Astellas Pharma Inc - Key Facts
Astellas Pharma Inc - Key Employees
Astellas Pharma Inc - Key Employee Biographies
Astellas Pharma Inc - Major Products and Services
Astellas Pharma Inc - History
Astellas Pharma Inc - Company Statement
Astellas Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

Section 2 – Company Analysis
Company Overview
Astellas Pharma Inc - Business Description
Product Category: OAB Products in Urology
Performance
Product Category: Other Products
Performance
Product Category: Prograf
Performance
Product Category: XTANDI
Performance
Geographical Segment: Asia and Oceana (Excluding Japan)
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: Japan
Performance
Geographical Segment: The Americas
Performance
R&D Overview
Astellas Pharma Inc - Corporate Strategy
Astellas Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Astellas Pharma Inc - Strengths
Astellas Pharma Inc - Weaknesses
Astellas Pharma Inc - Opportunities
Astellas Pharma Inc - Threats
Astellas Pharma Inc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Astellas Pharma Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments
Apr 10, 2019: Astellas and Concerto HealthAI to Launch Real-World Evidence Initiative on Acute Myeloid Leukemia Focused on Improving Patient Treatment and Outcomes
Apr 03, 2019: Astellas announces key senior leadership promotions and new hire in Medical and Development organization
Mar 05, 2019: ReForm Biologics announces collaboration agreement with Astellas Pharma
Jan 17, 2019: Actinium successfully completes first module of collaborative research program with Astellas; second module initiated
Jan 10, 2019: Astellas announces key Senior Leadership promotions and new hire in Medical and Development Organization
Dec 17, 2018: Astellas buys Potenza Therapeutics for up to $405m
Dec 17, 2018: Astellas Pharmaceuticals named in advertisements for breach of ABPI Code of Practice
Dec 12, 2018: Astellas promotes Lei Ding to vice president, payer strategy, contracts, and pricing
Nov 20, 2018: Astellas Global Health Foundation launches - Foundation to support improving access to health for underserved populations
Nov 15, 2018: Astellas Announces Construction of R&D and Manufacturing Facilities in Japan and US

Section 6 – Appendix
Methodology
Ratio Definitions
About the Publisher
Contact Us
Disclaimer

List of Tables
Astellas Pharma Inc, Key Facts
Astellas Pharma Inc, Key Employees
Astellas Pharma Inc, Key Employees (cont..)
Astellas Pharma Inc, Key Employee Biographies
Astellas Pharma Inc, Major Products and Services
Astellas Pharma Inc, History
Astellas Pharma Inc, Other Locations
Astellas Pharma Inc, Subsidiaries
Astellas Pharma Inc, Joint Venture
Astellas Pharma Inc, Key Competitors
Astellas Pharma Inc, Ratios based on current share price
Astellas Pharma Inc, Annual Ratios
Astellas Pharma Inc, Annual Ratios (Cont...1)
Astellas Pharma Inc, Annual Ratios (Cont...2)
Astellas Pharma Inc, Interim Ratios
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Astellas Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Astellas Pharma Inc, Performance Chart (2015 - 2019)
Astellas Pharma Inc, Ratio Charts
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Kyowa Hakko Kirin Co Ltd
  • Otsuka Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Ceylon Tobacco Company PLC
  • Takeda Pharmaceutical Co Ltd
  • Stealth BioTherapeutics Corp
Note: Product cover images may vary from those shown
Adroll
adroll